Skip to main content
Respiratory medicine
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores.
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS).
Variability in chest radiology interpretation between thoracic and non-thoracic radiologists: Implications for pulmonary fibrosis care.
Palliative care referrals in patients with pulmonary arterial hypertension: The Pulmonary Hypertension Association Registry.
Actigraphy informs distinct patient-centered outcomes in Pre-COPD.
Exposures and associations with clinical phenotypes in hypersensitivity pneumonitis: A scoping review.
CXCL9 and CXCL10 are differentially associated with systemic organ involvement and pulmonary disease severity in sarcoidosis.
Serum CXCL11 correlates with pulmonary outcomes and disease burden in sarcoidosis.
Airflow limitation classified with the fixed ratio or the lower limit of normal and cause-specific mortality - A prospective study.
NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.
